Overview and Scope
Transmucosal drug delivery devices are medical devices designed to deliver drugs through the mucous membranes, such as those in the mouth, nose, or rectum, for rapid absorption into the bloodstream. These devices are used to administer medications that are poorly absorbed by the gastrointestinal tract or that require quick onset of action, such as pain relief or hormone therapy. Their purpose is to bypass the digestive system, providing a more direct and efficient route for drug delivery.
Sizing and Forecast
The transmucosal drug delivery devices market size has grown strongly in recent years. It will grow from $46.16 billion in 2023 to $50.24 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to the need for rapid relief from angina, the effectiveness of sublingual delivery for quick absorption into the bloodstream, desire to bypass gastrointestinal degradation, development of buccal tablets, the need for non-invasive delivery of peptides and proteins.
The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $71.69 billion in 2028 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to the development of smart drug delivery systems, increased prevalence of chronic diseases, growing focus on personalized medicine, aging population with higher medication needs, and increased awareness. Major trends in the forecast period include expansion in therapeutic applications, customizing drug delivery devices for personalized medicine, regulatory approvals and guidelines, emerging markets, eco-friendly devices, and innovative formulations.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/transmucosal-drug-delivery-devices-global-market-report
Segmentation & Regional Insights
The transmucosal drug delivery devices market covered in this report is segmented –
1) By Type: Passive Transdermal Drug Delivery, Active Transdermal Drug Delivery
2) By Drug Type: Buccal Tablets, Oral Sprays, Sublingual Films And Wafers, Gels, Medicated Confectionery, Other Drug Types
3) By Indication: Pain Management, Addiction Treatment, Hormonal Therapies, Others Indications
4) By End User: Academic And Research Institutes, Pharmaceutical And Biotechnology Companies, Diagnostic Laboratories, Hospitals
North America was the largest region in the transmucosal drug delivery devices market in 2023. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16812&type=smp
Major Driver Impacting Market Growth
The growing prevalence of chronic diseases is expected to propel the growth of the transmucosal drug delivery devices market going forward. A chronic disease refers to a long-lasting condition that typically progresses slowly and persists over time, often requiring ongoing medical management to control symptoms and prevent complications. Chronic diseases are rising as a result of, lifestyle factors, aging populations, environmental factors, healthcare system challenges, and urbanization. Transmucosal drug delivery devices are used in chronic diseases to provide controlled and efficient delivery of medications, ensuring sustained therapeutic levels for managing symptoms and improving patient adherence. For instance, in July 2021, according report published by the International Diabetes Federation (IDF), a Belgium-based national diabetes association, about 537 million people worldwide have diabetes. The number of cases has been increasing over the past few decades, and the IDF predicts 783 million people will have diabetes by 2045 an increase of 46%. Therefore, the increasing prevalence of chronic diseases is driving the growth of the transmucosal drug delivery devices market.
Key Industry Players
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Becton Dickinson and Company, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Lifevision Healthcare Private Limited, Noven Pharmaceuticals, SAVA Healthcare Limited, Antares Pharma Inc., Kaizen Pharmaceuticals Pvt. Ltd., Lucky Pharma Pvt. Ltd., Maya Biotech Pvt. Ltd, AdvaCare Pharma LLP, Satsuma Pharmaceuticals Inc., Biophar Lifesciences Private Limited, Fibovil Pharmaceuticals Private Limited, Slan Medicinal Holdings Ltd.
The transmucosal drug delivery devices market report table of contents includes:
1. Executive Summary
2. Transmucosal Drug Delivery Devices Market Characteristics
3. Transmucosal Drug Delivery Devices Market Trends And Strategies
4. Transmucosal Drug Delivery Devices Market – Macro Economic Scenario
5. Global Transmucosal Drug Delivery Devices Market Size and Growth
.
.
.
32. Global Transmucosal Drug Delivery Devices Market Competitive Benchmarking
33. Global Transmucosal Drug Delivery Devices Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Transmucosal Drug Delivery Devices Market
35. Transmucosal Drug Delivery Devices Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
